NCT07063407View on ClinicalTrials.gov

Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

May 31, 2027

Conditions
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
DRUG

HS-20093 in combination with Adebrelimab

HS-20093 in combination with Adebrelimab will be administered intravenously every 3 weeks until disease progression or other criteria for termination of treatment are met.

All Listed Sponsors
lead

Shanghai Hansoh Biomedical Co., Ltd

INDUSTRY